Ivana Strazic Geljic

Dr. Ivana Strazic Geljic

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2012 in Biochemical Pharmacology
Verified
Journal Article
Closed access
EVElise Verron
Elise Verron
ALA. Loubat
A. Loubat
GCG.F. Carle
G.F. Carle
CVC. Vignes-Colombeix
C. Vignes-Colombeix
IGIvana Strazic Geljic
Ivana Strazic Geljic
JSJean-Claude Scimeca
Jean-Claude Scimeca

12 January 2017 in Journal of Tissue Engineering and Regenerative Medicine
Verified
Journal Article
Closed access
PDF file
IGIvana Strazic Geljic
Ivana Strazic Geljic
NMNicolas Melis
Nicolas Melis
FBFlorian Boukhechba
Florian Boukhechba
SSSébastien Schaub
Sébastien Schaub
CMCharlotte Mellier
Charlotte Mellier
JSJean-Claude Scimeca
Jean-Claude Scimeca

Verified
Journal Article
Open access
PDF file
IGIvana Strazic Geljic
Ivana Strazic Geljic
Paola Kučan BrlićPaola Kučan Brlić
Paola Kučan Brlić
LMLucija Musak
Lucija Musak
DKDubravka Karner
Dubravka Karner
Andreja Ambriovic-RistovAndreja Ambriovic-Ristov
Andreja Ambriovic-Ristov
TRTihana Lenac Rovis
Tihana Lenac Rovis
Numerous viruses hijack cellular protein trafficking pathways to mediate cell entry or to rearrange membrane structures thereby promoting viral replication and antagonizing the immune response. Adaptor protein complexes (AP), which mediate protein sorting in endocytic and secretory transport pathways, are one of the conserved viral targets with many viruses possessing AP-interacting motifs. We present here different mechanisms of viral interference with AP complexes and the functional consequences that allow for efficient viral propagation and evasion of host immune defense. The ubiquity of this phenomenon is evidenced by the fact that there are representatives for AP interference in all major viral families, covered in this review. The best described examples are interactions of human immunodeficiency virus and human herpesviruses with AP complexes. Several other viruses, like Ebola, Nipah, and SARS-CoV-2, are pointed out as high priority disease-causative agents supporting the need for deeper understanding of virus-AP interplay which can be exploited in the design of novel antiviral therapies.

1 September 2016 in Biochemical Pharmacology
Verified
Journal Article
Closed access
IGIvana Strazic Geljic
Ivana Strazic Geljic
IGIva Guberovic
Iva Guberovic
BDBlanka Didak
Blanka Didak
HSHeidy Schmid-Antomarchi
Heidy Schmid-Antomarchi
ASAnnie Schmid-Alliana
Annie Schmid-Alliana
EVElise Verron
Elise Verron

13 January 2020 in eLife
Verified
Journal Article
Open access
IGIvana Strazic Geljic
Ivana Strazic Geljic
Paola Kučan BrlićPaola Kučan Brlić
Paola Kučan Brlić
GAGuillem Angulo
Guillem Angulo
IBIlija Brizic
Ilija Brizic
BLBerislav Lisnic
Berislav Lisnic
TRTihana Lenac Rovis
Tihana Lenac Rovis
Cytomegaloviruses (CMVs) are ubiquitous pathogens known to employ numerous immunoevasive strategies that significantly impair the ability of the immune system to eliminate the infected cells. Here, we report that the single mouse CMV (MCMV) protein, m154, downregulates multiple surface molecules involved in the activation and costimulation of the immune cells. We demonstrate that m154 uses its cytoplasmic tail motif, DD, to interfere with the adaptor protein-1 (AP-1) complex, implicated in intracellular protein sorting and packaging. As a consequence of the perturbed AP-1 sorting, m154 promotes lysosomal degradation of several proteins involved in T cell costimulation, thus impairing virus-specific CD8+ T cell response and virus control in vivo. Additionally, we show that HCMV infection similarly interferes with the AP-1 complex. Altogether, we identify the robust mechanism employed by single viral immunomodulatory protein targeting a broad spectrum of cell surface molecules involved in the antiviral immune response.